Anemia News and Research

RSS

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.

Stored red blood cells lose ability to release key anti-adhesive molecule

Donated red blood cells lose a key feature that diminishes their lifesaving power the longer they have been stored, according to researchers at Duke University Medical Center.

16 Jul 2011

Eisai's DACOGEN sNDA for acute myeloid leukemia accepted by FDA for review

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that Eisai Inc. today released information that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental New Drug Application (sNDA) seeking approval of DACOGEN (decitabine) for injection in the treatment of acute myeloid leukemia.

14 Jul 2011

FDA accepts Eisai's DACOGEN sNDA for review to treat acute myeloid leukemia

Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental New Drug Application (sNDA) seeking approval of DACOGEN (decitabine) for injection in the treatment of acute myeloid leukemia.

13 Jul 2011

Positive results from sarilumab Phase 2b trial on RA, ankylosing spondylitis

Sanofi and Regeneron Pharmaceuticals, Inc. announced results from Phase 2b trials in rheumatoid arthritis (RA) and ankylosing spondylitis (AS) with sarilumab, a novel, high-affinity, subcutaneously administered, fully-human antibody targeting the interleukin-6 receptor.

13 Jul 2011

genOway acquires worldwide exclusive license for RMCE technology from bluebird bio for genetically modified rodents

genOway and bluebird bio report today genOway acquisition of an exclusive worldwide license for the RMCE technology (developed at the Massachusetts Institute of Technology) in the field of genetically modified rodents.

12 Jul 2011

Alnylam seeks CTA clearance to initiate ALN-PCS Phase I clinical trial for severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical trial with ALN-PCS, an RNAi therapeutic for the treatment of severe hypercholesterolemia.

11 Jul 2011

Corporates profit from pinkwashing

Companies that try to increase sales of their products by adopting the color pink and pink ribbons to imply that they support breast cancer research-a practice called pinkwashing-but at the same time permit the use of chemicals shown to cause cancer are committing a form of social injustice against women, according to a thought-provoking article in Environmental Justice.

8 Jul 2011

Transplants with half-matched bone marrow or cord blood are comparable to fully matched tissue

Identifying a suitable donor for leukemia and lymphoma patients who need bone marrow transplants may be far easier now that results of two clinical trials show transplant results with half-matched bone marrow or umbilical cord blood are comparable to fully matched tissue, thanks in large part to the availability of effective antirejection drugs and special post-transplant chemotherapy.

8 Jul 2011

Half-matched transplants widen donor pool for leukemia and lymphoma

7 Jul 2011

Amrubicin vs. topotecan Phase III trial against lung cancer presented at IASLC conference

Lung cancer patients given amrubicin (Calsed) as a second-line therapy had a significantly improved response rate and longer progression-free survival than patients treated with topotecan (Hycamtin), according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.

7 Jul 2011

Simple blood test for melanoma-inhibitory activity could detect neurofibromas

Neurofibromatosis (NF1) is a genetic condition which affects one in every 3,000 people. The severity of symptoms can range from benign 'café au lait' patches on the skin, through small tumors under the skin and deep plexiform neurofibromas, to malignant tumors of the nerve sheath.

4 Jul 2011

Anacor, DNDi and SCYNEXIS complete SCYX-7158 pre-clinical studies for combating sleeping sickness

Anacor Pharmaceuticals, the Drugs for Neglected Diseases initiative (DNDi), and SCYNEXIS Inc. today announced the successful completion of pre-clinical studies for the first new oral drug candidate discovered specifically to combat human African trypanosomiasis (HAT), also known as sleeping sickness.

29 Jun 2011

FDA directive on anemia drug in kidney disease patients

The U.S. Food and Drug Administration (FDA) has issued new warnings for anemia drugs for patients with kidney disease after studies suggested such drugs could increase stroke risks. The new warnings are the latest to hit the widely used medications since 2007, when the FDA first said they could cause fatal side effects.

27 Jun 2011

FDA recommends conservative dosing guidelines for ESAs to treat anemia in patients with CKD

The U.S. Food and Drug Administration today recommended more conservative dosing guidelines for Erythropoiesis-Stimulating Agents (ESAs) when used to treat anemia in patients with chronic kidney disease (CKD) because of the increased risks of cardiovascular events such as stroke, thrombosis, and death.

27 Jun 2011

Maternal MS not linked with poor pregnancy or birth outcomes

Canadian researchers have found that maternal multiple sclerosis (MS) is generally not associated with adverse delivery outcomes or risk to their offspring. Full findings now appear in Annals of Neurology, a journal published by Wiley-Blackwell on behalf of the American Neurological Association.

27 Jun 2011

Health Canada grants market authorization for Sanofi-aventis Jevtana to treat prostate cancer

Sanofi-aventis announced today that Health Canada has granted market authorization for Jevtana injection in combination with prednisone for the treatment of patients with metastatic castration resistant prostate cancer, previously treated with a docetaxel-containing treatment regimen.

24 Jun 2011

FDA grants Orphan Drug Designation for Accentia's Revimmune to treat two autoimmune diseases

Accentia Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Revimmune, the Company's proprietary system-of-care based on high-dose administration of Cytoxan, for the treatment of two autoimmune disease indications, systemic sclerosis and autoimmune hemolytic anemia.

24 Jun 2011

Los Alamos National Lab scientists win three R&D Magazine's 2011 awards

Los Alamos National Laboratory scientists have won three of R&D Magazine's 2011 R&D100 Awards. Recognized as the "Oscars of Invention" by the Chicago Tribune, these awards honor the top 100 proven technological advances of the past year.

23 Jun 2011

Incivek-combination therapy increases chances of HCV patients achieving viral cure

The drug Incivek, when given in combination with two other medications, can dramatically increase the chances of people chronically infected with untreated genotype 1 hepatitis C virus achieving a viral cure. That's the finding of a study published in the June 23rd issue of the New England Journal of Medicine.

23 Jun 2011

MUHC/McGill parasite disease researcher wins CPHA International Public Health Award

With close to one third of the world's population infected with parasitic worms, MUHC researcher Dr. Theresa Gyorkos is thinking big when it comes to finding a solution to this global public health challenge. As part of an international research and policy team, she is contributing to the soon-to-be-released WHO Strategic Plan to control intestinal worm infections in more than 100 countries.

23 Jun 2011

Anemia News and Research

Further Reading

Stored red blood cells lose ability to release key anti-adhesive molecule

Eisai's DACOGEN sNDA for acute myeloid leukemia accepted by FDA for review

FDA accepts Eisai's DACOGEN sNDA for review to treat acute myeloid leukemia

Positive results from sarilumab Phase 2b trial on RA, ankylosing spondylitis

genOway acquires worldwide exclusive license for RMCE technology from bluebird bio for genetically modified rodents

Alnylam seeks CTA clearance to initiate ALN-PCS Phase I clinical trial for severe hypercholesterolemia

Corporates profit from pinkwashing

Transplants with half-matched bone marrow or cord blood are comparable to fully matched tissue

Half-matched transplants widen donor pool for leukemia and lymphoma

Amrubicin vs. topotecan Phase III trial against lung cancer presented at IASLC conference

Simple blood test for melanoma-inhibitory activity could detect neurofibromas

Anacor, DNDi and SCYNEXIS complete SCYX-7158 pre-clinical studies for combating sleeping sickness

FDA directive on anemia drug in kidney disease patients

FDA recommends conservative dosing guidelines for ESAs to treat anemia in patients with CKD

Maternal MS not linked with poor pregnancy or birth outcomes

Health Canada grants market authorization for Sanofi-aventis Jevtana to treat prostate cancer

FDA grants Orphan Drug Designation for Accentia's Revimmune to treat two autoimmune diseases

Los Alamos National Lab scientists win three R&D Magazine's 2011 awards

Incivek-combination therapy increases chances of HCV patients achieving viral cure

MUHC/McGill parasite disease researcher wins CPHA International Public Health Award

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News